Division of Affitech AS
Latest From Pharmexa AS
Appointments: Eli Lilly, Alexion, Actelion, Polyphor, Constellation, Bone Therapeutics and Allied Minds
This week's roundup includes the announced retirement of Lilly's CFO, high-level appointments by Alexion Pharmaceuticals, Actelion and Constellation, and board elections by Wilson Therapeutics, Bone Therapeutics and Atlantic Healthcare.
Hopes for what would have been the first therapeutic vaccine for pancreatic cancer have been dashed by the Phase III failure of KAEL-GemVax's GV1001, forcing the South Korean firm to reconsider the future strategy for its lead development project.
A telomerase peptide oncovaccine being developed by the South Korean group KAEL-GemVax and already in a major Phase III programme for pancreatic cancer has also shown clinical promise in the treatment of non-small cell lung cancer (NSCLC).
Being part of a large listed group relieves KAEL-GemVax from the constant fundraising headaches typical of its peers, writes Ian Haydock. This article is part of the 2011 Scrip Asia 100.
- Antisense, Oligonucleotides
- Large Molecule
- Therapeutic Areas
- M&E Biotech AS
- Western Europe
- Parent & Subsidiaries
- Affitech AS
- Senior Management
Achim Kaufhold, MD, PhD, CEO
Claude Mikkelsen, SVP, Fin. & Investor Relations
Mark J Newman, PhD, SVP, Research
Dana Leach, PhD, SVP, Bus. Dev. & IP
- Contact Info
Phone: (45) 45 16 25 25
Agern Allé 1
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.